LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.

    Viteri, Santiago / Minchom, Anna / Bazhenova, Lyudmila / Ou, Sai-Hong Ignatius / Bauml, Joshua M / Shell, Scott A / Schaffer, Michael / Gu, Junchen / Rose, Jennifer B / Curtin, Joshua C / Mahadevia, Parthiv / Girard, Nicolas

    Molecular oncology

    2022  Volume 17, Issue 2, Page(s) 230–237

    Abstract: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR-mutant nonsmall cell lung cancers. We analysed real-world datasets to determine the frequency of ex20ins variants, and the ability of polymerase ... ...

    Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR-mutant nonsmall cell lung cancers. We analysed real-world datasets to determine the frequency of ex20ins variants, and the ability of polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify them. Three real-world United States NGS databases were used: GENIE, FoundationInsights, and GuardantINFORM. Mutation profiles consistent with in-frame EGFR ex20ins were summarized. GENIE, FoundationInsights, and GuardantINFORM datasets identified 180, 627, and 627 patients with EGFR ex20ins respectively. The most frequent insertion region of exon 20 was the near loop (~ 70%), followed by the far loop (~ 30%) and the helical (~ 3-6%) regions. GENIE, FoundationInsights, and GuardantINFORM datasets identified 41, 102, and 96 unique variants respectively. An analysis of variants projected that ~ 50% of EGFR ex20ins identified by NGS would have been missed by PCR-based assays. Given the breadth of EGFR ex20ins identified in the real-world US datasets, the ability of PCR to identify these mutations is limited. NGS platforms are more appropriate to identify patients likely to benefit from EGFR ex20ins-targeted therapies.
    MeSH term(s) Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Mutagenesis, Insertional/genetics ; ErbB Receptors/genetics ; Mutation/genetics ; Exons/genetics ; Genomics ; Protein Kinase Inhibitors
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2022-11-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2415106-3
    ISSN 1878-0261 ; 1574-7891
    ISSN (online) 1878-0261
    ISSN 1574-7891
    DOI 10.1002/1878-0261.13327
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prevalence, Treatment Patterns, and Outcomes of Individuals with

    O'Sullivan, Dylan E / Jarada, Tamer N / Yusuf, Amman / Hu, Leo Xun Yang / Gogna, Priyanka / Brenner, Darren R / Abbie, Erica / Rose, Jennifer B / Eaton, Kiefer / Elia-Pacitti, Julia / Ewara, Emmanuel M / Pabani, Aliyah / Cheung, Winson Y / Boyne, Devon J

    Current oncology (Toronto, Ont.)

    2022  Volume 29, Issue 10, Page(s) 7198–7208

    Abstract: Real-world evidence ... ...

    Abstract Real-world evidence surrounding
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Gefitinib/therapeutic use ; Afatinib/therapeutic use ; Erlotinib Hydrochloride/therapeutic use ; ErbB Receptors/genetics ; Prevalence ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Platinum/therapeutic use ; Antineoplastic Agents/therapeutic use ; Exons ; Mutation ; Alberta
    Chemical Substances Gefitinib (S65743JHBS) ; Afatinib (41UD74L59M) ; Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1) ; Platinum (49DFR088MY) ; Antineoplastic Agents
    Language English
    Publishing date 2022-09-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1236972-x
    ISSN 1718-7729 ; 1198-0052
    ISSN (online) 1718-7729
    ISSN 1198-0052
    DOI 10.3390/curroncol29100567
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m

    Rapattoni, Wally / Zante, David / Tomas, Marko / Myageri, Varun / Golden, Shane / Grover, Prerna / Tehrani, Ali / Millson, Brad / Tobe, Sheldon W / Rose, Jennifer B

    Diabetes, obesity & metabolism

    2021  Volume 23, Issue 4, Page(s) 916–928

    Abstract: Aim: To better understand the healthcare burden of people with type 2 diabetes (T2D) and estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m: Materials and methods: We used administrative data to evaluate the prevalence of T2D, eGFR < 90 ... ...

    Abstract Aim: To better understand the healthcare burden of people with type 2 diabetes (T2D) and estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m
    Materials and methods: We used administrative data to evaluate the prevalence of T2D, eGFR < 90 mL/min/1.73 m
    Results: While the prevalence of T2D in the general population aged ≥ 30 years in Ontario increased by 1.8% over a 5-year period (2011-2012 to 2015-2016), the prevalence of eGFR < 90 mL/min/1.73 m
    Conclusions: This real-world retrospective study highlights an increasing prevalence of T2D, eGFR < 90 mL/min/1.73 m
    Language English
    Publishing date 2021-01-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14294
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Physiology of nucleoside transporters: back to the future. . . .

    Rose, Jennifer B / Coe, Imogen R

    Physiology (Bethesda, Md.)

    2008  Volume 23, Page(s) 41–48

    Abstract: Nucleoside transporters (NTs) are integral membrane proteins responsible for mediating and facilitating the flux of nucleosides and nucleobases across cellular membranes. NTs are also responsible for the uptake of nucleoside analog drugs used in the ... ...

    Abstract Nucleoside transporters (NTs) are integral membrane proteins responsible for mediating and facilitating the flux of nucleosides and nucleobases across cellular membranes. NTs are also responsible for the uptake of nucleoside analog drugs used in the treatment of cancer and viral infections, and they are the target of certain compounds used in the treatment of some types of cardiovascular disease. The important role of NTs as drug transporters and therapeutic targets has necessarily led to intense interest into their structure and function and the relationship between these proteins and drug efficacy. In contrast, we still know relatively little about the fundamental physiology of NTs. In this review, we discuss various aspects of the physiology of NTs in mammalian systems, particularly noting tissues and cells where there has been little recent research. Our central thesis is reference back to some of the older literature, combined with current findings, will provide direction for future research into NT physiology that will lead to a fuller understanding of the role of these intriguing proteins in the everyday lives of cells, tissues, organs, and whole animals.
    MeSH term(s) Adipose Tissue/metabolism ; Animals ; Antineoplastic Agents/metabolism ; Antiviral Agents/metabolism ; Cardiovascular Agents/pharmacology ; Cardiovascular System/metabolism ; Central Nervous System/metabolism ; Gastrointestinal Tract/metabolism ; Humans ; Kidney/metabolism ; Liver/metabolism ; Muscle, Skeletal/metabolism ; Nucleoside Transport Proteins/drug effects ; Nucleoside Transport Proteins/metabolism ; Nucleosides/metabolism
    Chemical Substances Antineoplastic Agents ; Antiviral Agents ; Cardiovascular Agents ; Nucleoside Transport Proteins ; Nucleosides
    Language English
    Publishing date 2008-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2158667-6
    ISSN 1548-9221 ; 1548-9213
    ISSN (online) 1548-9221
    ISSN 1548-9213
    DOI 10.1152/physiol.00036.2007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Rose, Jennifer B / Sorabji, Delna / Bajaj, Harpreet S

    Canadian journal of diabetes

    2019  Volume 43, Issue 7, Page(s) 464–471

    Abstract: Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.: Methods: CANadian CAnagliflozin REgistry (CanCARE) is a ... ...

    Abstract Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.
    Methods: CANadian CAnagliflozin REgistry (CanCARE) is a prospective, observational, single-arm, real-world Canadian study of the effectiveness and safety of CANA for the treatment of T2DM in 527 subjects. PRO measures were collected in CanCARE using the Current Health Satisfaction Questionnaire (CHES-Q) at baseline and after 3, 6 and 12 months of CANA treatment to examine patient satisfaction regarding weight and overall health. Associations between changes in satisfaction with weight, systolic blood pressure (SBP) and glycated hemoglobin (A1C) levels were also investigated.
    Results: Proportion of patients satisfied with their body weight and overall health increased from 22.1% and 26.9% at baseline to 32.4% and 49.2% after 12 months of CANA treatment, respectively. Satisfaction rates also increased on CHES-Q domains representing physical and emotional health. Correlations were found between improvement in satisfaction with body weight and weight loss (r=-0.29; p<0.01) and between improvements in satisfaction with overall health and weight loss (r=-0.13; p=0.03) and SBP (r=-0.17; p<0.01), but not with changes in A1C level.
    Conclusions: Treatment with CANA is associated with improvements in satisfaction with body weight and overall health, which may be important drivers of patient self-management and hold the potential to positively influence long-term outcomes in T2DM.
    MeSH term(s) Blood Glucose/analysis ; Body Weight ; Canada ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Prospective Studies ; Registries/statistics & numerical data ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Surveys and Questionnaires ; Weight Loss
    Chemical Substances Blood Glucose ; Sodium-Glucose Transporter 2 Inhibitors ; Canagliflozin (0SAC974Z85)
    Language English
    Publishing date 2019-04-16
    Publishing country Canada
    Document type Journal Article ; Observational Study
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2019.04.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line.

    Naydenova, Zlatina / Rose, Jennifer B / Coe, Imogen R

    American journal of physiology. Heart and circulatory physiology

    2008  Volume 294, Issue 6, Page(s) H2687–92

    Abstract: The purine nucleoside adenosine is a physiologically important molecule in the heart. Brief exposure of cardiomyocytes to hypoxic challenge results in the production of extracellular adenosine, which then interacts with adenosine receptors to activate ... ...

    Abstract The purine nucleoside adenosine is a physiologically important molecule in the heart. Brief exposure of cardiomyocytes to hypoxic challenge results in the production of extracellular adenosine, which then interacts with adenosine receptors to activate compensatory signaling pathways that lead to cellular resistance to subsequence hypoxic challenge. This phenomenon is known as preconditioning (PC), and, while adenosine is clearly involved, other components of the response are less well understood. Flux of nucleosides, such as adenosine and inosine, across cardiomyocyte membranes is dependent on equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). We have previously shown in the murine cardiomyocyte HL-1 cell line that hypoxic challenge leads to an increase in intracellular adenosine, which exits the cell via ENT1 and preconditions via A1 and A3 adenosine receptor-dependent mechanisms. However, the role and contribution of inosine and ENT2 are unclear. In this study, we confirmed that ENT1 and ENT2 are both capable of transporting inosine. Moreover, we found that hypoxic challenge leads to a significant increase in levels of intracellular inosine, which exits the cell via both ENT1 and ENT2. Exogenously added inosine (5 microM) preconditions cardiomyocytes in an A1 adenosine receptor-dependent manner since preconditioning can be blocked by the A1 adenosine receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (1 microM) but not the A3 adenosine receptor antagonist MRS-1220 (200 nM). These data suggest that cardiomyocyte responses to hypoxic PC are more complex than previously thought, involving both adenosine and inosine and differing, but overlapping, contributions of the two ENT isoforms.
    MeSH term(s) Adenosine/metabolism ; Adenosine A1 Receptor Antagonists ; Adenosine A3 Receptor Antagonists ; Animals ; Cell Hypoxia ; Cell Line ; Cell Survival ; Equilibrative Nucleoside Transporter 1 ; Equilibrative-Nucleoside Transporter 2/metabolism ; Inosine/metabolism ; Mice ; Myocytes, Cardiac/drug effects ; Myocytes, Cardiac/metabolism ; Myocytes, Cardiac/pathology ; Nucleoside Transport Proteins/antagonists & inhibitors ; Nucleoside Transport Proteins/metabolism ; Quinazolines/pharmacology ; Receptor, Adenosine A1/metabolism ; Receptor, Adenosine A3/metabolism ; Thioinosine/analogs & derivatives ; Thioinosine/pharmacology ; Triazoles/pharmacology ; Up-Regulation ; Xanthines/pharmacology
    Chemical Substances 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline ; Adenosine A1 Receptor Antagonists ; Adenosine A3 Receptor Antagonists ; Equilibrative Nucleoside Transporter 1 ; Equilibrative-Nucleoside Transporter 2 ; Nucleoside Transport Proteins ; Quinazolines ; Receptor, Adenosine A1 ; Receptor, Adenosine A3 ; SLC29A1 protein, mouse ; Slc29a2 protein, mouse ; Triazoles ; Xanthines ; Thioinosine (46S541971T) ; Inosine (5A614L51CT) ; 1,3-dipropyl-8-cyclopentylxanthine (9PTP4FOI9E) ; 4-nitrobenzylthioinosine (GV1L2DZM2Z) ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2008-04-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603838-4
    ISSN 1522-1539 ; 0363-6135
    ISSN (online) 1522-1539
    ISSN 0363-6135
    DOI 10.1152/ajpheart.00251.2007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity.

    Ramadan, Azza / Naydenova, Zlatina / Stevanovic, Katarina / Rose, Jennifer B / Coe, Imogen R

    Purinergic signalling

    2013  Volume 10, Issue 2, Page(s) 305–312

    Abstract: The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. ENT1 is well established to play a role in adenosinergic signaling in the cardiovascular system by modulating adenosine levels. Moderate ... ...

    Abstract The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. ENT1 is well established to play a role in adenosinergic signaling in the cardiovascular system by modulating adenosine levels. Moderate ethanol consumption is cardioprotective and underlying mechanisms of action are not clear although adenosinergic signaling has been implicated. Here, we show that ethanol (5-200 mM) significantly reduces ENT1-dependent [(3)H] 2-chloroadenosine uptake (by up to 27 %) in the cardiomyocyte cell line, HL-1. Inhibition or absence of ENT1 is known to be cardioprotective, suggesting that the interaction of ethanol with ENT1 may promote adenosinergic cardioprotective pathways in the cardiovasculature.Ethanol sensitivity of adenosine uptake is altered by pharmacological activation of PKA and PKC. Primary cardiomyocytes from PKCε-null mice have significantly greater sensitivity to inhibition (by approximately 37 %) of adenosine uptake by ethanol than controls. These data suggest that the presence of ethanol may compromise ENT1-dependent nucleoside analog drug cytotoxicity, and indeed, ethanol (5 mM) reduces the cytotoxic effects of gemcitabine (2 nM), an anti-cancer drug, in the human cancer cell line, HTB2. Thus, the pharmacological inhibition of ENT1 by ethanol may contribute to ethanol-dependent cardioprotection but compromise gemcitabine cytotoxicity.
    MeSH term(s) Adenosine/metabolism ; Animals ; Antimetabolites, Antineoplastic/toxicity ; Cell Line ; Cell Survival/drug effects ; Central Nervous System Depressants/pharmacology ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/toxicity ; Equilibrative Nucleoside Transporter 1/metabolism ; Ethanol/pharmacology ; Humans ; Mice ; Mice, Knockout ; Myocytes, Cardiac/drug effects ; Myocytes, Cardiac/metabolism ; Protein Kinase C-epsilon/metabolism
    Chemical Substances Antimetabolites, Antineoplastic ; Central Nervous System Depressants ; Equilibrative Nucleoside Transporter 1 ; SLC29A1 protein, human ; SLC29A1 protein, mouse ; Deoxycytidine (0W860991D6) ; Ethanol (3K9958V90M) ; gemcitabine (B76N6SBZ8R) ; Protein Kinase C-epsilon (EC 2.7.11.13) ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2013-10-27
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2172143-9
    ISSN 1573-9546 ; 1573-9538
    ISSN (online) 1573-9546
    ISSN 1573-9538
    DOI 10.1007/s11302-013-9391-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Culham, Matthew D / Rose, Jennifer B / Rapattoni, Wally / Bajaj, Harpreet S

    Diabetes, obesity & metabolism

    2018  Volume 21, Issue 3, Page(s) 691–699

    Abstract: Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate ... ...

    Abstract Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada.
    Materials and methods: SGLT2i-naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m
    Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (-0.90%; 95% CI, -1.02, -0.78) and at 12 months (-1.04%; 95% CI, -1.15, -0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (-4.65 mm Hg); body weight (-3.24 kg), waist circumference (-2.91 cm) and body mass index (-1.15 kg/m
    Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real-world setting, confirming findings from randomized controlled trials.
    MeSH term(s) Adult ; Aged ; Canada ; Canagliflozin/adverse effects ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Electronic Health Records/statistics & numerical data ; Female ; General Practice/statistics & numerical data ; Humans ; Male ; Middle Aged ; Registries ; Treatment Outcome
    Chemical Substances Canagliflozin (0SAC974Z85)
    Language English
    Publishing date 2018-12-05
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.13573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Nucleoside transporter expression profiles in human cardiac tissue show striking individual variability with overall predominance of hENT1.

    Marvi, Melissa / Rose, Jennifer B / Bang, Andrew / Moon, Byung Choo / Pozeg, Zlatko / Ibrahim, Moheb / Peniston, Charles / Coe, Imogen R

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

    2010  Volume 41, Issue 5, Page(s) 685–691

    Abstract: Nucleoside transporters (NTs) are integral membrane transport proteins that modulate the flux of nucleosides such as adenosine across cell membranes. Two families of NTs exist, the concentrative NTs (CNTs, SLC28) and the equilibrative NTs (ENTs, SLC29). ... ...

    Abstract Nucleoside transporters (NTs) are integral membrane transport proteins that modulate the flux of nucleosides such as adenosine across cell membranes. Two families of NTs exist, the concentrative NTs (CNTs, SLC28) and the equilibrative NTs (ENTs, SLC29). CNTs and ENTs transport anti-cancer and anti-viral nucleoside analog drugs and ENTs are also targets of drugs used to treat cardiac pathologies. Levels of some NT profiles have been shown to relate to clinical outcomes in the use of nucleoside analog drugs. However, currently, patient NT profile is not assessed prior to pharmacological administration of analog drugs. Here we describe a reliable method to determine a complete individual NT expression profile from human tissue using quantitative real-time PCR. We developed this assay on tissue (right atrial appendage, left internal mammary, aorta) from individuals undergoing cardiac surgery and compared these findings to the NT expression profiles in pooled whole heart tissue (normal and diseased). Data show that hENT1 is the most abundantly expressed NT, with highest expression levels in the aorta. However, NT expression profiles are highly variable among individuals and changes in NT expression between normal and diseased tissues were observed. These data are the first to describe the RNA expression patterns of all seven NT isoforms in the human heart. The methodology described here may be useful for quantitatively characterizing complete NT expression profiles in any human target tissue.
    MeSH term(s) Adenosine/metabolism ; Adult ; Aged ; Aorta/metabolism ; Biological Assay/methods ; Biological Transport ; Cardiovascular Diseases/metabolism ; Cardiovascular Diseases/physiopathology ; Equilibrative Nucleoside Transporter 1/genetics ; Equilibrative Nucleoside Transporter 1/metabolism ; Gene Expression Regulation ; Humans ; Male ; Membrane Transport Proteins/genetics ; Membrane Transport Proteins/metabolism ; Middle Aged ; Myocardium/metabolism ; Nucleosides/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism
    Chemical Substances Equilibrative Nucleoside Transporter 1 ; Membrane Transport Proteins ; Nucleosides ; RNA, Messenger ; SLC29A1 protein, human ; cif nucleoside transporter ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2010-12-23
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1154366-8
    ISSN 1879-0720 ; 0928-0987
    ISSN (online) 1879-0720
    ISSN 0928-0987
    DOI 10.1016/j.ejps.2010.09.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection.

    Rose, Jennifer B / Naydenova, Zlatina / Bang, Andrew / Eguchi, Megumi / Sweeney, Gary / Choi, Doo-Sup / Hammond, James R / Coe, Imogen R

    American journal of physiology. Heart and circulatory physiology

    2009  Volume 298, Issue 3, Page(s) H771–7

    Abstract: To better understand the role of equilibrative nucleoside transporters (ENT) in purine nucleoside-dependent physiology of the cardiovascular system, we investigated whether the ENT1-null mouse heart was cardioprotected in response to ischemia (coronary ... ...

    Abstract To better understand the role of equilibrative nucleoside transporters (ENT) in purine nucleoside-dependent physiology of the cardiovascular system, we investigated whether the ENT1-null mouse heart was cardioprotected in response to ischemia (coronary occlusion for 30 min followed by reperfusion for 2 h). We observed that ENT1-null mouse hearts showed significantly less myocardial infarction compared with wild-type littermates. We confirmed that isolated wild-type adult mouse cardiomyocytes express predominantly ENT1, which is primarily responsible for purine nucleoside uptake in these cells. However, ENT1-null cardiomyocytes exhibit severely impaired nucleoside transport and lack ENT1 transcript and protein expression. Adenosine receptor expression profiles and expression levels of ENT2, ENT3, and ENT4 were similar in cardiomyocytes isolated from ENT1-null adult mice compared with cardiomyocytes isolated from wild-type littermates. Moreover, small interfering RNA knockdown of ENT1 in the cardiomyocyte cell line, HL-1, mimics findings in ENT1-null cardiomyocytes. Taken together, our data demonstrate that ENT1 plays an essential role in cardioprotection, most likely due to its effects in modulating purine nucleoside-dependent signaling and that the ENT1-null mouse is a powerful model system for the study of the role of ENTs in the physiology of the cardiomyocyte.
    MeSH term(s) Animals ; Cell Line ; Cells, Cultured ; Disease Models, Animal ; Equilibrative Nucleoside Transporter 1/genetics ; Equilibrative Nucleoside Transporter 1/physiology ; Female ; Mice ; Mice, Transgenic ; Models, Animal ; Myocardial Reperfusion Injury/physiopathology ; Myocardial Reperfusion Injury/prevention & control ; Myocytes, Cardiac/cytology ; Myocytes, Cardiac/drug effects ; Myocytes, Cardiac/physiology ; Purine Nucleosides/metabolism ; RNA, Small Interfering/pharmacology ; Receptors, Purinergic P1/metabolism ; Signal Transduction/physiology
    Chemical Substances Equilibrative Nucleoside Transporter 1 ; Purine Nucleosides ; RNA, Small Interfering ; Receptors, Purinergic P1
    Language English
    Publishing date 2009-12-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603838-4
    ISSN 1522-1539 ; 0363-6135
    ISSN (online) 1522-1539
    ISSN 0363-6135
    DOI 10.1152/ajpheart.00711.2009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top